-transparent.png){kind=logo}
Sufficient increase in plasma of factor VIII activities with a view to carrying out surgery in mild and moderate Haemophilia A and von Willebrand's disease was achieved by intravenous infusion of 1-desamino-8-D-arginine vasopressin (DDAVP). 15 patients were treated with success and three patients had to be transfused with factor VIII concentrates to control postoperative hemorrhage. DDAVP therapy makes transfusion unnecessary in selected patients. This is an important therapeutic advance as long as the use of blood products does involve danger of infecting the recipient. Another advantage is that DDAVP therapy is much cheaper than factor VIII concentrate.
Related Publications
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
November 1989,
Ugeskrift for laeger,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
October 1984,
Schweizerische medizinische Wochenschrift,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
January 1978,
The American journal of the medical sciences,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
October 1984,
Acta endocrinologica,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
June 1988,
Boletin medico del Hospital Infantil de Mexico,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
November 1974,
Deutsche medizinische Wochenschrift (1946),
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
June 1988,
The Journal of pediatrics,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
June 1984,
Klinische Wochenschrift,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
January 1974,
Scottish medical journal,
G E Tjønnfjord, and
S A Evensen, and
H Stormorken, and
S Trebo
June 1974,
British journal of haematology,
